Shots: The approval of Verzenio is based on results of two P-III and one P-II study. The P-III MONARCH 3 study assessing Verzenio + anastrozole/letrozole vs PBO in 493 postmenopausal […]readmore
Tags : canada
Shots: The launch of Onstryv follows its Health Canada approval received on Jan 15, 2019 as an add-on therapy to a levodopa regimen indicated to treat signs and symptoms of […]readmore
Shots: Moberg to receive $14.6M as upfront and milestone payments of $4.6M for development and regulatory ($0.5M initial payment) and $10M on commercialization of product Moberg will be responsible for […]readmore